Approved for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL) is brexucabtagene autoleucel (brex-cel; Tecartus; KTE-X19), a CD19 CART construct similar to axi-cel (146). The gene discussed is CD19; the disease is mantle cell lymphoma.